Search

Your search keyword '"de Brouwer, Remco"' showing total 21 results
Start Over Author "de Brouwer, Remco"
21 results on '"de Brouwer, Remco"'

3. ECG-only explainable deep learning algorithm predicts the risk for malignant ventricular arrhythmia in phospholamban cardiomyopathy

Author

van de Leur, Rutger R., de Brouwer, Remco, Bleijendaal, Hidde, Verstraelen, Tom E., Mahmoud, Belend, Perez-Matos, Ana, Dickhoff, Cathelijne, Schoonderwoerd, Bas A., Germans, Tjeerd, Houweling, Arjan, van der Zwaag, Paul A., Cox, Moniek G.P.J., Peter van Tintelen, J., te Riele, Anneline S.J.M., van den Berg, Maarten P., Wilde, Arthur A.M., Doevendans, Pieter A., de Boer, Rudolf A., and van Es, René

Published
2024
Full Text
View/download PDF

4. Penetrance and Prognosis of MYH7 Variant-Associated Cardiomyopathies: Results From a Dutch Multicenter Cohort Study

Author

Jansen, Mark, de Brouwer, Remco, Hassanzada, Fahima, Schoemaker, Angela E., Schmidt, Amand F., Kooijman-Reumerman, Maria D., Bracun, Valentina, Slieker, Martijn G., Dooijes, Dennis, Vermeer, Alexa M.C., Wilde, Arthur A.M., Amin, Ahmad S., Lekanne Deprez, Ronald H., Herkert, Johanna C., Christiaans, Imke, de Boer, Rudolf A., Jongbloed, Jan D.H., van Tintelen, J. Peter, Asselbergs, Folkert W., and Baas, Annette F.

Published
2024
Full Text
View/download PDF

7. Long-term reliability of the phospholamban (PLN) p.(Arg14del) risk model in predicting major ventricular arrhythmia: a landmark study

Author

van der Heide, Myrthe Y C, primary, Verstraelen, Tom E, additional, van Lint, Freyja H M, additional, Bosman, Laurens P, additional, de Brouwer, Remco, additional, Proost, Virginnio M, additional, van Drie, Esmée, additional, Taha, Karim, additional, Zwinderman, Aeilko H, additional, Dickhoff, Cathelijne, additional, Schoonderwoerd, Bas A, additional, Germans, Tjeerd, additional, Houweling, Arjan C, additional, Gimeno-Blanes, Juan R, additional, van der Zwaag, Paul A, additional, de Boer, Rudolf A, additional, Cox, Moniek G P J, additional, van Tintelen, J Peter, additional, and Wilde, Arthur A M, additional

Published
2024
Full Text
View/download PDF

11. Penetrance and Prognosis of MYH7 Variant-Associated Cardiomyopathies

Author

Jansen, Mark, primary, de Brouwer, Remco, additional, Hassanzada, Fahima, additional, Schoemaker, Angela E., additional, Schmidt, Amand F., additional, Kooijman-Reumerman, Maria D., additional, Bracun, Valentina, additional, Slieker, Martijn G., additional, Dooijes, Dennis, additional, Vermeer, Alexa M.C., additional, Wilde, Arthur A.M., additional, Amin, Ahmad S., additional, Lekanne Deprez, Ronald H., additional, Herkert, Johanna C., additional, Christiaans, Imke, additional, de Boer, Rudolf A., additional, Jongbloed, Jan D.H., additional, van Tintelen, J. Peter, additional, Asselbergs, Folkert W., additional, and Baas, Annette F., additional

Published
2023
Full Text
View/download PDF

12. A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Author

de Brouwer, Remco, primary, te Rijdt, Wouter P, additional, Hoorntje, Edgar T, additional, Amin, Ahmad, additional, Asselbergs, Folkert W, additional, Cox, Moniek G P J, additional, van der Heijden, Jeroen F, additional, Hillege, Hans, additional, Karper, Jacco C, additional, Mahmoud, Belend, additional, van der Meer, Peter, additional, Oomen, Anton, additional, te Riele, Anneline S J M, additional, Silljé, Herman H W, additional, Tan, Hanno L, additional, van Tintelen, Jan Peter, additional, van Veldhuisen, Dirk J, additional, Westenbrink, Berend Daan, additional, Wiesfeld, Ans C P, additional, Willems, Tineke P, additional, van der Zwaag, Paul A, additional, Wilde, Arthur A M, additional, de Boer, Rudolf A, additional, and van den Berg, Maarten P, additional

Published
2023
Full Text
View/download PDF

13. Penetrance and Prognosis of MYH7Variant-Associated Cardiomyopathies

Author

Jansen, Mark, de Brouwer, Remco, Hassanzada, Fahima, Schoemaker, Angela E., Schmidt, Amand F., Kooijman-Reumerman, Maria D., Bracun, Valentina, Slieker, Martijn G., Dooijes, Dennis, Vermeer, Alexa M.C., Wilde, Arthur A.M., Amin, Ahmad S., Lekanne Deprez, Ronald H., Herkert, Johanna C., Christiaans, Imke, de Boer, Rudolf A., Jongbloed, Jan D.H., van Tintelen, J. Peter, Asselbergs, Folkert W., and Baas, Annette F.

Abstract

MYH7variants cause hypertrophic cardiomyopathy (HCM), noncompaction cardiomyopathy (NCCM), and dilated cardiomyopathy (DCM). Screening of relatives of patients with genetic cardiomyopathy is recommended from 10 to 12 years of age onward, irrespective of the affected gene.

Published
2024
Full Text
View/download PDF

15. Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation

Author

Eijgenraam, Tim R., primary, Stege, Nienke M., additional, Oliveira Nunes Teixeira, Vivian, additional, de Brouwer, Remco, additional, Schouten, Elisabeth M., additional, Grote Beverborg, Niels, additional, Sun, Liu, additional, Später, Daniela, additional, Knöll, Ralph, additional, Hansson, Kenny M., additional, Amilon, Carl, additional, Janzén, David, additional, Yeh, Steve T., additional, Mullick, Adam E., additional, van der Meer, Peter, additional, de Boer, Rudolf A., additional, and Silljé, Herman H. W., additional

Published
2022
Full Text
View/download PDF

17. Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers

Author

Taha, Karim, primary, Verstraelen, Tom E, additional, de Brouwer, Remco, additional, de Bruin-Bon, Rianne H A C M, additional, Cramer, Maarten J, additional, Te Rijdt, Wouter P, additional, Bouma, Berto J, additional, de Boer, Rudolf A, additional, Doevendans, Pieter A, additional, Asselbergs, Folkert W, additional, Wilde, Arthur A M, additional, van den Berg, Maarten P, additional, and Teske, Arco J, additional

Published
2021
Full Text
View/download PDF

18. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction

Author

Verstraelen, Tom E, primary, van Lint, Freyja H M, additional, Bosman, Laurens P, additional, de Brouwer, Remco, additional, Proost, Virginnio M, additional, Abeln, Bob G S, additional, Taha, Karim, additional, Zwinderman, Aeilko H, additional, Dickhoff, Cathelijne, additional, Oomen, Toon, additional, Schoonderwoerd, Bas A, additional, Kimman, Gerardus P, additional, Houweling, Arjan C, additional, Gimeno-Blanes, Juan R, additional, Asselbergs, Folkert W, additional, van der Zwaag, Paul A, additional, de Boer, Rudolf A, additional, van den Berg, Maarten P, additional, van Tintelen, J Peter, additional, and Wilde, Arthur A M, additional

Published
2021
Full Text
View/download PDF

21. Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers.

Author

Taha K, Verstraelen TE, de Brouwer R, de Bruin-Bon RHACM, Cramer MJ, Te Rijdt WP, Bouma BJ, de Boer RA, Doevendans PA, Asselbergs FW, Wilde AAM, van den Berg MP, and Teske AJ

Subjects
Humans, Echocardiography methods, Mutation, Risk Assessment, Stroke Volume, Ventricular Function, Left, Cardiomyopathies, Ventricular Dysfunction, Left diagnostic imaging, Ventricular Dysfunction, Left genetics
Abstract

Aims: Phospholamban (PLN) p.Arg14del mutation carriers are at risk of developing malignant ventricular arrhythmias (VAs) and/or heart failure. Currently, left ventricular ejection fraction (LVEF) plays an important role in risk assessment for VA in these individuals. We aimed to study the incremental prognostic value of left ventricular mechanical dispersion (LVMD) by echocardiographic deformation imaging for prediction of sustained VA in PLN p.Arg14del mutation carriers., Methods and Results: We included 243 PLN p.Arg14del mutation carriers, which were classified into three groups according to the '45/45' rule: (i) normal left ventricular (LV) function, defined as preserved LVEF ≥45% with normal LVMD ≤45 ms (n = 139), (ii) mechanical LV dysfunction, defined as preserved LVEF ≥45% with abnormal LVMD >45 ms (n = 63), and (iii) overt LV dysfunction, defined as reduced LVEF <45% (n = 41). During a median follow-up of 3.3 (interquartile range 1.8-6.0) years, sustained VA occurred in 35 individuals. The negative predictive value of having normal LV function at baseline was 99% [95% confidence interval (CI): 92-100%] for developing sustained VA. The positive predictive value of mechanical LV dysfunction was 20% (95% CI: 15-27%). Mechanical LV dysfunction was an independent predictor of sustained VA in multivariable analysis [hazard ratio adjusted for VA history: 20.48 (95% CI: 2.57-162.84)]., Conclusion: LVMD has incremental prognostic value on top of LVEF in PLN p.Arg14del mutation carriers, particularly in those with preserved LVEF. The '45/45' rule is a practical approach to echocardiographic risk stratification in this challenging group of patients. This approach may also have added value in other diseases where LVEF deterioration is a relative late marker of myocardial dysfunction., Competing Interests: Conflict of interest: The University Medical Center Groningen, which employs several of the authors, has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Novo Nordisk, and Roche. R.A.d.B. received speaker fees from Abbott, AstraZeneca, Novartis, and Roche., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results